A randomized controlled study comparing reverse hybrid therapy and standard triple therapy for helicobacter pylori infection

Medicine (United States)

Volumn 94, Issue 48, 2015, Pages

  Hsu, Ping I ^a   Kao, Sung Shuo ^a   Wu, Deng Chyang ^b,c,d   Chen, Wen Chi ^a   Peng, Nan Jing ^b   Yu, Hsien Chung ^a   Wang, Huay Min ^a   Lai, Kwok Hun ^a   Cheng, Jin Shiu ^a   Chen, Angela ^e,f   Chuah, Seng Kee ^g,h,i,j   Tsay, Feng Woe ^a  

^a Division of Gastroenterology   (Taiwan)

^b Department of Internal Medicine ^*  (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f Institute of Biomedical Science   (Taiwan)

^g NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^h Department of Internal Medicine   (Taiwan)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTACID AGENT; CLARITHROMYCIN; CYTOCHROME P450 2C19; METRONIDAZOLE; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; CYP2C19 PROTEIN, HUMAN; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CLEARANCE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; GENOTYPE; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; TREATMENT DURATION; VOMITING; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; SINGLE BLIND PROCEDURE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CYTOCHROME P-450 CYP2C19; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; SINGLE-BLIND METHOD;

EID: 84952312371     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002104     Document Type: Article

References (39)

1. Sung JJY, Chung SCS, Ling TKW, et al. Antibacterial treatment of gastric ulcer associated with Helicobacter pylori. N Engl J Med. 1995; 332: 139-142.
2. Hunt RH, Lam SK. Helicobacter pylori: from art to a science. J Gastroenterol Hepatol. 1998; 13: 21-28.
3. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347: 1175-1186.
4. Isaacson PG. Recent developments in our understanding of gastric lymphomas. Am J Surg Pathol. 1996; 20(Suppl. 1): 1-7.
5. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004; 291: 189-194.
6. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24: 1587-1600.
7. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010; 15: 1-20.
8. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012; 61: 646-664.
9. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102: 1808-1825.
10. Graham DY, Akiko S. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 321-331.
11. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53: 1374-1384.
12. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterl. 2010; 105: 65-73.
13. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol. 2004; 10: 668-671.
14. Bigard MA, Delchier JC, Riachi G, et al. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998; 12: 383-388.
15. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15- year period in Italy. J Antimicrob Chemother. 2007; 59: 783-785.
16. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007; 56: 1353-1357.
17. Hsu PI, Wu DC, Chen WC, et al. Comparison of 7-day triple, 10- day sequential and 7-day concomitant therapies for Helicobacter pylori infection-a randomized controlled trial. Antimicrob Agents Chemother. 2014; 214: 5936-5942.
18. Gisbert JP, Calvet X. Non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2011; 34: 604-617.
19. Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastroenterol. 2011; 4: 103-114.
20. Hsu PI, Wu DC, Wu JY, et al. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011; 16: 139-145.
21. Sardarian H, Fakheri H, Hosseini V, et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter. 2013; 18: 129-134.
22. De Francesco V, Hassan C, Ridola L, et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol. 2014; 63: 748-752.
23. Oh DH, Lee DH, Kang KK, et al. The efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol. 2014; 29: 1171-1176.
24. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013; 145: 121-128.
25. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011; 8: 79-88.
26. Chuah SK, Tsay FW, Hsu PI, et al. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 2011; 17: 3971-3975.
27. Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: a paradigm shift to improved efficacy. Gastroenterol Res Pract. 2012: 757926.
28. Wu JY, Hsu PI, Wu DC, et al. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014; 19: 207-213.
29. Tsay FW, Wu DC, Kao SS, et al. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. Helicobacter. 2015; 20: 71-77.
30. Hsu PI, Lai KH, Lau CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology. 2011; 140: 791-798.
31. Wu DC, Hsu PI, Tseng HH, et al. Helicobacter pylori Infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine. 2011; 90: 180-185.
32. Hsu PI, Wu DC, Wu JY, et al. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011; 16: 146-152.
33. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole-versus pantoprazole based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005; 100: 2387-2392.
34. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol. 2010; 8: 36-41.
35. Federico A, Gravina AG, Miranda A, et al. Eradication of Helicobacter pylori infection: which regimen first? World J Gastroenterol. 2014: 20665-20672.
36. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014; 12: 177-186.
37. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2012; 381: 205-213.
38. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005; 20: 153-167.
39. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother. 2009; 63: 1017-1024.